285 related articles for article (PubMed ID: 21075824)
1. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity.
Martin-Killias P; Stefan N; Rothschild S; Plückthun A; Zangemeister-Wittke U
Clin Cancer Res; 2011 Jan; 17(1):100-10. PubMed ID: 21075824
[TBL] [Abstract][Full Text] [Related]
2. Increasing the antitumor effect of an EpCAM-targeting fusion toxin by facile click PEGylation.
Simon M; Stefan N; Borsig L; Plückthun A; Zangemeister-Wittke U
Mol Cancer Ther; 2014 Feb; 13(2):375-85. PubMed ID: 24184633
[TBL] [Abstract][Full Text] [Related]
3. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.
Stefan N; Zimmermann M; Simon M; Zangemeister-Wittke U; Plückthun A
Bioconjug Chem; 2014 Dec; 25(12):2144-56. PubMed ID: 25350699
[TBL] [Abstract][Full Text] [Related]
4. A recombinant immunotoxin derived from a humanized epithelial cell adhesion molecule-specific single-chain antibody fragment has potent and selective antitumor activity.
Di Paolo C; Willuda J; Kubetzko S; Lauffer I; Tschudi D; Waibel R; Plückthun A; Stahel RA; Zangemeister-Wittke U
Clin Cancer Res; 2003 Jul; 9(7):2837-48. PubMed ID: 12855664
[TBL] [Abstract][Full Text] [Related]
5. Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo.
Sokolova E; Proshkina G; Kutova O; Shilova O; Ryabova A; Schulga A; Stremovskiy O; Zdobnova T; Balalaeva I; Deyev S
J Control Release; 2016 Jul; 233():48-56. PubMed ID: 27178808
[TBL] [Abstract][Full Text] [Related]
6. Designing the furin-cleavable linker in recombinant immunotoxins based on Pseudomonas exotoxin A.
Weldon JE; Skarzynski M; Therres JA; Ostovitz JR; Zhou H; Kreitman RJ; Pastan I
Bioconjug Chem; 2015 Jun; 26(6):1120-8. PubMed ID: 25997032
[TBL] [Abstract][Full Text] [Related]
7. Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.
Liu H; Lindbo S; Ding H; Altai M; Garousi J; Orlova A; Tolmachev V; Hober S; Gräslund T
Int J Oncol; 2019 Jul; 55(1):309-319. PubMed ID: 31180549
[TBL] [Abstract][Full Text] [Related]
8. Modular Conjugation of a Potent Anti-HER2 Immunotoxin Using Coassociating Peptides.
Stoessel A; Groysbeck N; Guyot L; Barret L; Nominé Y; Nguekeu-Zebaze L; Bender A; Voilquin L; Lutz T; Pallaoro N; Blocat M; Deville C; Masson M; Zuber G; Chatton B; Donzeau M
Bioconjug Chem; 2020 Oct; 31(10):2421-2430. PubMed ID: 32996763
[TBL] [Abstract][Full Text] [Related]
9. A guide to taming a toxin--recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer.
Weldon JE; Pastan I
FEBS J; 2011 Dec; 278(23):4683-700. PubMed ID: 21585657
[TBL] [Abstract][Full Text] [Related]
10. Cytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A.
Gholami N; Cohan RA; Razavi A; Bigdeli R; Dashbolaghi A; Asgary V
J Cell Physiol; 2020 Apr; 235(4):3711-3720. PubMed ID: 31578716
[TBL] [Abstract][Full Text] [Related]
11. A chemical conjugate between HER2-targeting antibody fragment and Pseudomonas exotoxin A fragment demonstrates cytotoxic effects on HER2-expressing breast cancer cells.
Lee S; Park S; Nguyen MT; Lee E; Kim J; Baek S; Kim CJ; Jang YJ; Choe H
BMB Rep; 2019 Aug; 52(8):496-501. PubMed ID: 30670149
[TBL] [Abstract][Full Text] [Related]
12. Efficient cell-specific uptake of binding proteins into the cytoplasm through engineered modular transport systems.
Verdurmen WP; Luginbühl M; Honegger A; Plückthun A
J Control Release; 2015 Feb; 200():13-22. PubMed ID: 25526701
[TBL] [Abstract][Full Text] [Related]
13. Antibody internalization studied using a novel IgG binding toxin fusion.
Mazor Y; Barnea I; Keydar I; Benhar I
J Immunol Methods; 2007 Apr; 321(1-2):41-59. PubMed ID: 17336321
[TBL] [Abstract][Full Text] [Related]
14. Targeting TARP, a novel breast and prostate tumor-associated antigen, with T cell receptor-like human recombinant antibodies.
Epel M; Carmi I; Soueid-Baumgarten S; Oh S; Bera T; Pastan I; Berzofsky J; Reiter Y
Eur J Immunol; 2008 Jun; 38(6):1706-20. PubMed ID: 18446790
[TBL] [Abstract][Full Text] [Related]
15. The novel immunotoxin HM1.24-ETA' induces apoptosis in multiple myeloma cells.
Staudinger M; Glorius P; Burger R; Kellner C; Klausz K; Günther A; Repp R; Klapper W; Gramatzki M; Peipp M
Blood Cancer J; 2014 Jun; 4(6):e219. PubMed ID: 24927408
[TBL] [Abstract][Full Text] [Related]
16. Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors.
Zielinski R; Lyakhov I; Jacobs A; Chertov O; Kramer-Marek G; Francella N; Stephen A; Fisher R; Blumenthal R; Capala J
J Immunother; 2009 Oct; 32(8):817-25. PubMed ID: 19752752
[TBL] [Abstract][Full Text] [Related]
17. A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.
Tsai AK; Oh S; Chen H; Shu Y; Ohlfest JR; Vallera DA
J Neurooncol; 2011 Jun; 103(2):255-66. PubMed ID: 20830604
[TBL] [Abstract][Full Text] [Related]
18. Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
Singh R; Samant U; Hyland S; Chaudhari PR; Wels WS; Bandyopadhyay D
Mol Cancer Ther; 2007 Feb; 6(2):562-9. PubMed ID: 17308054
[TBL] [Abstract][Full Text] [Related]
19. Creation and anti-cancer potency in HeLa cells of a novel chimeric toxin, HMGNCIDIN, composed of HMGN2 a-helical domain and PE38 KDEL domain III.
Xiong WB; Huang N; Feng Y; Wu Q; Wang BY
Chin Med J (Engl); 2008 Jan; 121(1):82-5. PubMed ID: 18208672
[No Abstract] [Full Text] [Related]
20.
Chang J; Liu X; Ren H; Lu S; Li M; Zhang S; Zhao K; Li H; Zhou X; Peng L; Liu Z; Hu P
Mol Pharm; 2021 Jun; 18(6):2285-2297. PubMed ID: 33998814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]